Invention Grant
- Patent Title: Oncolytic vaccinia virus cancer therapy
-
Application No.: US14656397Application Date: 2015-03-12
-
Publication No.: US09226977B2Publication Date: 2016-01-05
- Inventor: David Kirn
- Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
- Applicant Address: US CA San Francisco
- Assignee: SillaJen Biotherapeutics, Inc.
- Current Assignee: SillaJen Biotherapeutics, Inc.
- Current Assignee Address: US CA San Francisco
- Agency: Morgan, Lewis & Bockius LLP
- Main IPC: A61K48/00
- IPC: A61K48/00 ; A61K9/00 ; A61K38/19 ; A61K45/06 ; A61K35/768

Abstract:
Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
Public/Granted literature
- US20150202325A1 ONCOLYTIC VACCINIA VIRUS CANCER THERAPY Public/Granted day:2015-07-23
Information query